The introduction of the fixed-dose NRTI combination pills Kivexa (abacavir and 3TC, called Epzicom in the US) and Truvada (tenofovir and FTC) in summer 2004 “ushered in a new treatment era for antiretroviral-naïve patients initiating antiretroviral therapy”, write American researchers in the October 1st edition of AIDS. After the introduction of these combination pills, the investigators found that the amount of time patients remained on first-line treatment increased significantly.
Ease of dosing and improved tolerability were identified by the researchers as the main reasons why patients were able to remain on their treatment for longer.
http://www.aidsmap.com/en/news/E80376F8-17E1-4A7F-9FC9-DD963A3B5E56.asp